PMID- 29741118
OWN - NLM
STAT- MEDLINE
DCOM- 20191219
LR  - 20191219
IS  - 1724-6075 (Electronic)
IS  - 0391-5603 (Linking)
VI  - 86
IP  - 1
DP  - 2019 Feb
TI  - 15 years' survey of safety and efficacy of Serenoa repens extract in benign 
      prostatic hyperplasia patients with risk of progression.
PG  - 17-22
LID - 10.1177/0391560318772466 [doi]
AB  - AIM: The aim of this study is to investigate the efficacy and safety of long-term 
      therapy with Serenoa repens extract with regard to halting benign prostatic 
      hyperplasia progression. MATERIAL AND METHODS: An open non-comparative 
      observational study of the continuous use of S. repens plant extract at a dosage 
      of 320 mg once a day for 15 years was performed in 30 patients at risk for benign 
      prostatic hyperplasia progression. Changes in IPSS (International Prostatic 
      Symptoms Scale) and QoL (Quality of life) scores and changes in Qmax, voided 
      volume, residual urine volume, and prostate volume were evaluated during the 
      study. RESULTS: The study showed an absence of progression based on both 
      subjective (the sum of scores on the IPSS and QoL scales) and objective (prostate 
      volume, urination rate, residual urine volume) criteria. Furthermore, the 
      patients had no adverse events related to the study drug, including prostate 
      cancer. CONCLUSIONS: The 15 years' study results suggest that taking S. repens 
      plant extract continuously at a daily dose of 320 mg is an effective and safe way 
      to prevent the progression of benign prostatic hyperplasia.
FAU - Vinarov, Andrey Zinovievich
AU  - Vinarov AZ
AD  - 1 I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Spivak, Leonid Grigorievich
AU  - Spivak LG
AD  - 1 I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Platonova, Darina Vladimirovna
AU  - Platonova DV
AD  - 1 I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Rapoport, Leonid Mikhailovich
AU  - Rapoport LM
AD  - 2 Clinic of Urology, I.M. Sechenov First Moscow State Medical University, Moscow, 
      Russia.
FAU - Korolev, Dmitry Olegovich
AU  - Korolev DO
AD  - 1 I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20180509
PL  - United States
TA  - Urologia
JT  - Urologia
JID - 0417372
RN  - 0 (Plant Extracts)
SB  - IM
CIN - J Urol. 2020 Sep;204(3):593-594. PMID: 32552493
MH  - Disease Progression
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Phytotherapy
MH  - Plant Extracts/adverse effects/*therapeutic use
MH  - Prostatic Hyperplasia/*drug therapy
MH  - *Serenoa
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Benign prostatic hyperplasia
OT  - continuous use
OT  - plant extracts
OT  - risk of progression
EDAT- 2018/05/10 06:00
MHDA- 2019/12/20 06:00
CRDT- 2018/05/10 06:00
PHST- 2018/05/10 06:00 [pubmed]
PHST- 2019/12/20 06:00 [medline]
PHST- 2018/05/10 06:00 [entrez]
AID - 10.1177/0391560318772466 [doi]
PST - ppublish
SO  - Urologia. 2019 Feb;86(1):17-22. doi: 10.1177/0391560318772466. Epub 2018 May 9.